{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:01:08Z","timestamp":1768460468555,"version":"3.49.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","award":["G047417N"],"award-info":[{"award-number":["G047417N"]}],"id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","award":["G089515N"],"award-info":[{"award-number":["G089515N"]}],"id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","award":["VirEOS2.0"],"award-info":[{"award-number":["VirEOS2.0"]}],"id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"Universiteit Gent","doi-asserted-by":"publisher","award":["BOFEXP2017001002"],"award-info":[{"award-number":["BOFEXP2017001002"]}],"id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhepr.2022.100646","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:09:18Z","timestamp":1670249358000},"page":"100646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-6161","authenticated-orcid":false,"given":"Rani","family":"Burm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freya","family":"Van Houtte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-5578","authenticated-orcid":false,"given":"Lieven","family":"Verhoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Atef","family":"Mesalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7565","authenticated-orcid":false,"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Roingeard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5968-2542","authenticated-orcid":false,"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-234X","authenticated-orcid":false,"given":"Philip","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100646_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B Treatment: What we know now and what remains to Be researched","volume":"3","author":"Suk-Fong","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2022.100646_bib3","unstructured":"WHO hepatitis B fact sheet; 2022. [cited; Available from: Hepatitis B (who.int)"},{"key":"10.1016\/j.jhepr.2022.100646_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2022.100646_bib6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100646_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100646_bib8","doi-asserted-by":"crossref","first-page":"a021550","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhepr.2022.100646_bib9","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100646_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cmi.2020.02.031","article-title":"Treatment of hepatitis D, an unmet medical need","volume":"26","author":"Caviglia","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhepr.2022.100646_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2022.100646_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100646_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2022.100646_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib17","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(20)30651-6","article-title":"48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV\/HDV co-infection","volume":"73","author":"Wedemeyer","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib18","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with Peg-Interferon alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib20","article-title":"Bulevirtide for patients with compensated chronic hepatitis delta: a review","author":"Degasperi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100646_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cld.2021.06.011","article-title":"New treatments for chronic hepatitis B virus\/hepatitis D virus infection","volume":"25","author":"Sandmann","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100646_bib22","first-page":"2929","article-title":"Human B cell growth and differentiation in the spleen of immunodeficient mice","volume":"166","author":"Depraetere","year":"2001","journal-title":"J\u00a0Immunol (Baltimore, Md: 1950)"},{"key":"10.1016\/j.jhepr.2022.100646_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.20657","article-title":"Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera","volume":"41","author":"Meuleman","year":"2005","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(03)01388-3","article-title":"A\u00a0simple and rapid method to determine the zygosity of uPA-transgenic SCID mice","volume":"308","author":"Meuleman","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhepr.2022.100646_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104816","article-title":"Mechanisms of HBV immune evasion","volume":"179","author":"Kuipery","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2022.100646_bib26","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100646_bib27","first-page":"217","article-title":"Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers","author":"Hehle","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhepr.2022.100646_bib28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2013.11.010","article-title":"Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection","volume":"60","author":"Giersch","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/liv.14677","article-title":"Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in\u00a0vivo","volume":"41","author":"Giersch","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100646_bib30","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1016\/S0168-8278(16)00887-4","article-title":"Prevention of viral spread, viremia reduction and HBsAg clearance in hepatitis B and D coinfected humanized mice by a human neutralizing monoclonal antibody","volume":"2","author":"Corti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib31","article-title":"The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice","author":"Lempp","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhepr.2022.100646_bib32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/jhep.2002.31867","article-title":"Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties","volume":"35","author":"Galun","year":"2002","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib33","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","article-title":"Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2022.100646_bib34","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3389\/fimmu.2019.02290","article-title":"Human monoclonal antibodies as adjuvant treatment of chronic hepatitis B virus infection","volume":"10","author":"Cerino","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2022.100646_bib35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2011.08.026","article-title":"The option of HBIG-free prophylaxis against recurrent HBV","volume":"56","author":"Fox","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/jhep.2000.19789","article-title":"Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review","volume":"32","author":"Shouval","year":"2000","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125704","article-title":"A\u00a0human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity","volume":"10","author":"Cerino","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100646_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/19420862.2015.1134409","article-title":"A\u00a0human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect","volume":"8","author":"Wang","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jhepr.2022.100646_bib39","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jhepr.2022.100646_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B\u00a0cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jhepr.2022.100646_bib41","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2022.100646_bib42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"ACTIV-3\/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2022.100646_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2017.10.015","article-title":"A\u00a0novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in\u00a0vitro and in\u00a0vivo","volume":"148","author":"Desombere","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2022.100646_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2017.10.019","article-title":"Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1","volume":"514","author":"Mesalam","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.jhepr.2022.100646_bib45","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/hep.27196","article-title":"Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in\u00a0vitro resistance to SR-BI-targeting agents","volume":"60","author":"Vercauteren","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib46","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4014\/jmb.1803.03056","article-title":"Generation and characterization of a neutralizing human monoclonal antibody to hepatitis B virus PreS1 from a phage-displayed human synthetic Fab library","volume":"28","author":"Jo","year":"2018","journal-title":"J\u00a0Microbiol Biotechnol"},{"key":"10.1016\/j.jhepr.2022.100646_bib47","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/21645515.2020.1763686","article-title":"Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody","volume":"16","author":"Zankharia","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhepr.2022.100646_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coviro.2018.04.002","article-title":"Viral envelope-specific antibodies in chronic hepatitis B virus infection","volume":"30","author":"Corti","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhepr.2022.100646_bib49","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.1073\/pnas.0701279104","article-title":"Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanism","volume":"104","author":"Chi","year":"2007","journal-title":"Proc Natl Acad Sci United States America"},{"key":"10.1016\/j.jhepr.2022.100646_bib50","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1073\/pnas.0603316103","article-title":"Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci United States America"},{"key":"10.1016\/j.jhepr.2022.100646_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.09.014","article-title":"In\u00a0vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees","volume":"318","author":"Hong","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.jhepr.2022.100646_bib52","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1073\/pnas.90.7.3014","article-title":"Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen","volume":"90","author":"Ogata","year":"1993","journal-title":"Proc Nat Acade Sci USA"},{"key":"10.1016\/j.jhepr.2022.100646_bib53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.antiviral.2008.03.006","article-title":"Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees","volume":"79","author":"Kim","year":"2008","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2022.100646_bib54","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/jhep.2000.9632","article-title":"Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees","volume":"32","author":"Eren","year":"2000","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib55","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26738","article-title":"A\u00a0potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.jhepr.2022.100646_bib56","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100646_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.chom.2020.05.010","article-title":"A\u00a0combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jhepr.2022.100646_bib58","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S0618-8278(19)30089-1","article-title":"PS-077-Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model","volume":"70","author":"Kim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib59","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101205","article-title":"Advances in human monoclonal antibody therapy for HBV infection","volume":"53","author":"Beretta","year":"2022","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhepr.2022.100646_bib61","unstructured":"EMA Xolair product information. [cited; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xolair-epar-product-information_en.pdf."},{"key":"10.1016\/j.jhepr.2022.100646_bib62","unstructured":"EMA MabThera product information. [cited; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf."},{"key":"10.1016\/j.jhepr.2022.100646_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715036","article-title":"Clinical efficacy and safety of eculizumab for treating myasthenia gravis","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2022.100646_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhepr.2022.100646_bib65","series-title":"Drugs and lactation database (LactMed)","year":"2006"},{"key":"10.1016\/j.jhepr.2022.100646_bib66","first-page":"27","article-title":"A\u00a0simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J\u00a0Basic Clin Pharm"},{"key":"10.1016\/j.jhepr.2022.100646_bib67","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1128\/JVI.77.16.8882-8892.2003","article-title":"Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions","volume":"77","author":"Schilling","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2022.100646_bib68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.23778","article-title":"Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells","volume":"52","author":"Neumann","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib69","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/nbt1363","article-title":"The growth and potential of human antiviral monoclonal antibody therapeutics","volume":"25","author":"Marasco","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhepr.2022.100646_bib70","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2022.100646_bib71","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2022.100646_bib72","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.15252\/emmm.201606593","article-title":"Immunoregulatory functions of immune complexes in vaccine and therapy","volume":"8","author":"Wen","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jhepr.2022.100646_bib73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1126\/science.6231724","article-title":"Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen","volume":"224","author":"Celis","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2022.100646_bib74","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in\u00a0vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100646_bib75","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100646_bib76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/eji.200324717","article-title":"Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key","volume":"34","author":"Bachmann","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhepr.2022.100646_bib77","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhepr.2022.100646_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/21645515.2019.1689745","article-title":"Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance","volume":"16","author":"Whitacre","year":"2020","journal-title":"Hum Vaccin Immunother"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592200218X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592200218X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:30:41Z","timestamp":1762900241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592200218X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S258955592200218X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100646","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100646"}}